News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

April

17

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

23

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury,...

20

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety...

4

electroCore, Inc. Announces U.S. Department of Veterans Affairs Study of gammaCore Sapphire™ (Non-Invasive Vagus Nerve Stimulator) for the Treatment of Post-Traumatic Headache

Randomized, multi-center, double-blind, parallel, sham-controlled trial enrolling up to 100 veterans and directed by...

Recent developments